![Page 1: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/1.jpg)
Clinical Use of HPV DNA Testing
Thomas C. Wright, Jr.College of Physicians and Surgeons of Columbia
University
![Page 2: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/2.jpg)
Clinical Uses of HPV Testing
Spectrum of HPV associated disease
Clinical uses of HPV DNA testing
Topics to be covered:
![Page 3: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/3.jpg)
Anogenital HPV Infections
Latent infection - no identifiable lesion
Exophytic condylomas
Low-grade and high-grade neoplasia
Invasive cancersCervix, vulva, anus, penis, head &
neck, esophagus, conjunctiva
Spectrum of clinical expression
![Page 4: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/4.jpg)
Clinical Spectrum of Genital Infections
Latent Infection Genital Warts
![Page 5: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/5.jpg)
Clinical Spectrum of Genital Infections
CIN 2,3 Invasive Cancer
![Page 6: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/6.jpg)
Anogenital HPV Types
High-risk types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82
Possible high-risk 23, 53, 66
Low-risk types 6, 11, 40,, 42, 43, 44, 54, 61, 70, 72, 81
Munoz et al. (2003) NEJM
![Page 7: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/7.jpg)
Wright and Schiffman (2003) NEJM
Natural History of HPV Infections
![Page 8: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/8.jpg)
Clinical Uses of HPV Testing
Spectrum of HPV associated disease
Clinical uses of HPV DNA testing
Topics to be covered:
![Page 9: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/9.jpg)
HPV DNA Testing
Management of ASC - US
Secondary follow-up - abnormal Pap
Follow-up post treatment
Primary screening
Potential clinical uses:
![Page 10: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/10.jpg)
Atypical Squamous Cells -Undetermined Significance (ASC - US)
![Page 11: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/11.jpg)
HPV Testing for Detecting CIN 2,3 in ASC
Wright* 144 0.78 54% 0.67 63%Manos* 995 0.89 40% 0.76 39%Bergeron 111 0.83 43% 0.67 32%Lin 74 1.00 53% -- -- Shlay 200 0.93 31% -- -- Solomon* 2324 0.96 56% 0.85 58%
HPV Testing Cytology Author No. Pts Sens Refer Sens. Refer
*from liquid cytology
![Page 12: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/12.jpg)
2001 Consensus Guidelines
All three standard modalities are considered safe and effective (A I)
Because of costs, and patient convenience, "reflex" HPV testing is preferred if liquid-based cytology or co-collection available(A I)
Management of ASC-US:
![Page 13: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/13.jpg)
Management of ASC-US
About 2.5 million ASC-US per year in U.S.
70% - 80% of these are liquid-based cytology specimens
70% - 80% of these get "reflex" HPV DNA testing and growing
Status as of January 2004:
![Page 14: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/14.jpg)
HPV DNA Testing
Management of ASC - US
Secondary follow-up - abnormal Pap
Follow-up post treatment of CIN 2,3
Potential clinical uses:
![Page 15: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/15.jpg)
HPV DNA Testing
Management of ASC - US
Secondary follow-up - abnormal Pap
Follow-up post treatment
Primary screening
Potential clinical uses:
![Page 16: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/16.jpg)
HPV Testing for Screening
Who gets screened
Testing method and with or without Pap
Screening frequency
Management of screen positives and negatives
Questions to address:
![Page 17: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/17.jpg)
Prevalence of HR HPV DNA
Netherlands^ 13% 10% 2% 2%Costa Rica^ 10% 6% 3% 3%Newfoundland* 17% 12% 5% 4%UK*^ 3% 3% 5%France* 21% 20% 13% 11%
% HPV (+) by AgeCountry < 25 25-34 35-44 45+
* all women, women without SIL, ^ by PCR, by HC II
![Page 18: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/18.jpg)
HPV by PCR CIN3 +
0 %
5 %
10 %
15 %
20 %
25 %
18-19
20-24
25-29
30-34
25-29
20-24
18-19
35-50
30-34
35-50
Kulasingham SL et al JAMA 2002;288:1749-57.
Age-specific Prevalence of HPV and CIN 3 + in Planned Parenthood Study
![Page 19: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/19.jpg)
HPV Testing for Screening
Women 30 years and older
FDA approval
ACOG Practice Bulletin
ACS Guidelines & NCI Workshop
May change with increased data
Age to initiate testing:
![Page 20: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/20.jpg)
Primary Screening - Sensitivity: CIN 3+
Study No. Pap HPV Combo
Portland 10,031 52 71 81U.K. 9,761 90 94 98Mexico 6,115 58 95 97Costa Rica 6,176 82 94 97South Africa 2,925 84 90 93China 1,936 98 100 100Baltimore 1,040 50 100 100Germany 7,592 52 96 100
![Page 21: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/21.jpg)
Primary Screening - Specificity: CIN 3+
Study No. Pap HPV Combo
Portland 10,031 98 92 91U.K. 9,761 97 97 96Mexico 6,115 99 94 93Costa Rica 6,176 94 94 90South Africa 2,925 86 80 76China 1,936 76 83 68Baltimore 1,040 98 96 96Germany 7,592 99 96 95
![Page 22: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/22.jpg)
HPV Testing for Screening
Negativity for high-risk HPV identifies which women are at very low risk forhaving or developing CIN 2,3 over next 3 yrs
Allows targeted screening
Key advantage of using:
![Page 23: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/23.jpg)
Predictive Value of HPV
20,817 women with adequate cytology at enrollment (1994-1996)
Tested frozen CVL samples with HC II
Follow-up was with cytology and "standard workup" of abnormals
NCI - Kaiser Portland, OR cohort:
Sherman (2003) JNCI
![Page 24: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/24.jpg)
QuickTime™ and aGraphics decompressorare needed to see this picture.
0 0-9 9-21 21-33 33-45 45-122
0%
1%
2%
3%
4%
5%
6%
7%
8%
Length of Follow-up (mos)
Development of CIN 3 on Follow-up
HPV +
Pap & HPV Neg
![Page 25: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/25.jpg)
HPV Testing for Screening
NCI, ASCCP, and ACS sponsored an experts' workshop to develop guidance for using HPV for screening.
Meeting held February 2003
Interim Guidance:
Wright et al. Obst. Gynecol. (2004)
![Page 26: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/26.jpg)
NCI - ASCCP Interim GuidanceHPV DNA as an Adjunct to Cytology
HPV (-)ASC-US
BothNegative
Colposcopy
Pap> LSIL
Repeat Pap & HPV in 3 yrs in 12 mos
HPV (+)ASC-US
Results of HPV and Cytology
![Page 27: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/27.jpg)
HPV Testing for Screening
Will definitely produce some level of anxiety in almost all patients
Concern was that clinicians would immediately perform colposcopy to rule out high-grade neoplasia
Very expensive - overload the system
Key issue is HPV (+) / Cytology (-)
![Page 28: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/28.jpg)
LoSIL
HiSIL
Cancers
Deaths5,000
15,000
250,000
1,000,000
1,250,000 ASCUS1,250,000
1,875,000 (7.5% of 25 million) HPV (+)
![Page 29: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/29.jpg)
Patient's comments when told about availability of HPV DNA
testing for screening
"Why the hell am I having a Pap smear every year if its not really finding out what we really need to find out? I would be really upset."
Anhang et al. (2004) Cancer
![Page 30: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/30.jpg)
Screening is all about risk. So what's the
risk?
![Page 31: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/31.jpg)
HPV (+) and Cytology (-)
Clavel - France: 4.2%
Cuzick - England: 2.8%
Wright - South Africa: 7.8%
Risk for CIN 2+ at 6 mos:
![Page 32: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/32.jpg)
HPV (+) and Cytology (-)
Clavel - France:
10 of 10 CIN 2+
Cuzick - England:
9 of 9 CIN 2+
Wright - South Africa:
13 of 14 CIN 2+
Repeat HPV (+) @ 6 mos:
![Page 33: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/33.jpg)
HPV (+) and Cytology (-)
Clavel - France: 40%
Cuzick - England: 55%
Wright - South Africa: 60%
Rates of HPV persistence - 6 mos:
![Page 34: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/34.jpg)
Negative Cytology - HPV DNA Positive
Repeat both Pap & HPVIn 6 to 12 mos
HPV (-)ASC-US
High-risk HPV (+)
Colposcopy
BothNegative
Pap> LSIL
Repeat Pap & HPV in 12 mo. in 3 yrs
![Page 35: Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University](https://reader036.vdocument.in/reader036/viewer/2022062803/56649c975503460f949531a9/html5/thumbnails/35.jpg)
Clinical Uses of HPV Testing
Spectrum of HPV associated disease
Clinical uses of HPV DNA testing
Topics to be covered: